Lazotinib is an important first-line treatment option for EGFR mutation positive non-small cell lung cancer (NSCLC), particularly suitable for patients with brain metastases or those requiring enhanced efficacy.

1、 Drug name

1. Common name: Lazertinib

2. Product Name: LAZCLUZE ™。

2、 Indications

Suitable for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with EGFR exon 19 deletion or exon 21L858R substitution mutation confirmed by FDA approved testing.

3、 Specifications and characteristics

80mg tablets, 240mg tablets

4、 Main components

1. Active ingredient: Lazertinib mesylate.

2. Accessories: including cross-linked carboxymethyl cellulose sodium, magnesium stearate, mannitol, etc. The coating contains glycerol monooctanoate ester, iron oxide pigment, etc.

5、 Usage and dosage

1. Recommended dosage: 240mg orally once daily, in combination with Amivantamab, can be used before or after meals. Swallow the whole piece, do not crush or chew.

2. Omission treatment: If missed, make up for it within 12 hours; If it exceeds 12 hours, skip and take the medication on time next time.

3. Vomiting treatment: After vomiting, there is no need to take the next dose according to the original plan.

6、 Dose adjustment

1. First dose reduction: 240mg → 160mg (2 tablets 80mg).

2. Secondary reduction: 160mg → 80mg.

3. Serious adverse reactions: medication should be temporarily or permanently discontinued, such as recurrence of venous thromboembolism (VTE) or diagnosis of interstitial lung disease (ILD).

7、 Medication precautions

1. Diet: A high-fat diet does not affect drug efficacy.

2. Skin care: Sunscreen and use non-alcoholic moisturizer during and 2 months after treatment.

3. Anticoagulation prevention: Prophylactic anticoagulation (such as low molecular weight heparin) should be administered 4 months before treatment to avoid vitamin K antagonists.

8、 Medication for special populations

1. Pregnant women: May cause fetal damage, contraception should be used until 3 weeks after the last dose.

2. Breastfeeding period: Breastfeeding is prohibited within 3 weeks after discontinuation of medication.

3. Liver and kidney dysfunction: Mild to moderate without dose adjustment, severe with insufficient data.

9、 Adverse reactions

1. Common (≥ 20%) conditions include: rash, paronychia, infusion reactions (Amivantamab related), muscle pain, edema, etc;

2. Serious adverse reactions include VTE (36%), ILD (3.1%), severe rash (26%), and ocular toxicity (16%).

10、 Contraindications

There are currently no clear contraindications, but there are specific warnings (such as embryotoxicity).

11、 Drug interactions

1. CYP3A4 strong/medium acting inducers (such as rifampicin) can significantly reduce the blood concentration of razetonib and should be avoided in combination.

2. CYP3A4/BCRP substrates (such as midazolam and rosuvastatin) may require dose adjustment.

12、 Storage method

Store at room temperature of 20 ° C-25 ° C, allowing short-term exposure to 15 ° C-30 ° C.

Lazertinibinformation